Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protara TherapeuticsTARA -2.73%32 Market Cap is $220.60 Mil as of Aug. 02, 2026. GuruFocus rates TARA with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,423 Biotechnology companies, Protara Therapeutics ranks better than 59.94% on this metric.
Protara Therapeutics's quarterly market cap
increased
from Sep. 2025 ($167.85 Mil) to Dec. 2025 ($285.62 Mil) and
increased
from Dec. 2025 ($285.62 Mil) to Mar. 2026 ($286.84 Mil).
Protara Therapeutics's annual market cap
increased
from Dec. 2023 ($21.31 Mil) to Dec. 2024 ($185.04 Mil) and
increased
from Dec. 2024 ($185.04 Mil) to Dec. 2025 ($285.62 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Protara Therapeutics's Enterprise Value for Today is $87.87 Mil.
Protara Therapeutics (NAS:TARA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Protara Therapeutics Market Cap Related Terms
Protara Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Protara Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Protara Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protara Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Protara Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Protara Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protara Therapeutics (TARA) has a Market Cap of $220.60 Mil as of Aug. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Protara Therapeutics and its competitors. According to the industry distribution chart, Protara Therapeutics ranks #570 out of 1423 companies in the Biotechnology industry, placing it in the top 40.1%.
Is Protara Therapeutics' Market Cap too high?
Protara Therapeutics' current Market Cap is $220.60 Mil. The Biotechnology industry median Market Cap is 112.87. Protara Therapeutics' value of $220.60 Mil is 95.5% above this industry median. Based on the distribution chart, Protara Therapeutics ranks #570 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Protara Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Protara Therapeutics' Market Cap compare to TRDA and ACIU?
According to the Biotechnology industry distribution chart, Protara Therapeutics ranks #570 out of 1423 companies for Market Cap. This puts Protara Therapeutics in the upper half of its industry. The industry median Market Cap is 112.87. Protara Therapeutics' value of $220.60 Mil is 95.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.87, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protara Therapeutics's current Market Cap of $220.60 Mil is 95.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Protara Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 112.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protara Therapeutics's current Market Cap is $220.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protara Therapeutics stock overvalued right now?
Protara Therapeutics (TARA) has a current Market Cap of $220.60 Mil. The current Market Cap is $220.60 Mil and 95.5% above the Biotechnology industry median of 112.87. Protara Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Protara Therapeutics (TARA), the current Market Cap is $220.60 Mil as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
32GF Score
Get the complete analysis for TARA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARA has been successfully added to your 
